FDA approves Tylenol with Naproxen as the first non-prescription fixed-dose acetaminophen and naproxen sodium combination for 12-hour pain relief
- nuaxia
- 1天前
- 讀畢需時 2 分鐘
The approval provides adults and children aged 12 years and older with a single over-the-counter combination option that delivers both rapid and prolonged pain relief without requiring separate analgesic products.
The US Food and Drug Administration (FDA) has approved Tylenol with Naproxen (acetaminophen/naproxen sodium) for the temporary relief of pain, making it the first non-prescription fixed-dose combination of acetaminophen and naproxen sodium available in the United States.
The approval offers an additional over-the-counter pain management option for patients aged 12 years and older while providing a single-tablet formulation that combines two established non-opioid analgesics.
Field | Content |
Alert Type | Drug Approval |
Drug Name | Tylenol with Naproxen |
Indication | Temporary relief of pain in adults and children aged 12 years and older. |
Therapy Area(s) | Pain Management |
Geography | US (FDA) |
What Happened | On 24 July 2026, the FDA approved Tylenol with Naproxen (acetaminophen 325 mg/naproxen sodium 110 mg tablets) for over-the-counter temporary pain relief in adults and children aged 12 years and older. The approval establishes the product as the first non-prescription fixed-dose combination of acetaminophen and naproxen sodium, providing up to 12 hours of pain relief in a single tablet formulation. |
Why It Matters | The approval introduces a new over-the-counter treatment option that combines two well-established non-opioid analgesics in a fixed-dose product, potentially simplifying pain management for patients who would otherwise use separate acetaminophen and naproxen products. It expands the range of non-prescription analgesic options but does not alter existing safety precautions associated with acetaminophen- or NSAID-containing medicines. |
Supporting Context | While other over-the-counter products combine acetaminophen with a non-steroidal anti-inflammatory drug, this is the first to combine acetaminophen specifically with naproxen sodium. FDA-approved labelling includes standard warnings for both acetaminophen- and NSAID-containing products, including liver toxicity and pregnancy-related precautions. |
Key Takeaway | FDA approval adds the first fixed-dose acetaminophen and naproxen sodium combination to the US over-the-counter pain relief market, expanding non-prescription treatment choices for eligible patients. |
What to Watch | Monitor commercial availability following the FDA approval and how the product is incorporated into over-the-counter pain management recommendations and consumer use. |
Primary Source | |
Relevant Date | 24 July 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言